<div id="readability-page-1"><h3>Claim 55% Off TipRanks</h3><ul><li>Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions </li><li> Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks </li></ul>The latest update is out from Laekna, Inc. ( (HK:2105) ). Laekna, Inc. has called its annual general meeting for 5 June 2026 in Shanghai to seek shareholder approval of its 2025 audited financial statements and the re-election of two executive directors and one independent non-executive director. The company will also request authorization for the board to set director and auditor remuneration and to reappoint KPMG as auditor. In addition, the board is asking shareholders to grant a general mandate allowing directors to issue, allot, or deal with additional shares and related securities, up to 20% of the company’s issued share capital, excluding treasury shares. If approved, this mandate would give Laekna increased flexibility to raise capital and manage its equity structure, potentially supporting future growth initiatives and strategic financing activities. The most recent analyst rating on (HK:2105) stock is a Buy with a HK$24.16 price target. To see the full list of analyst forecasts on Laekna, Inc. stock, see the HK:2105 Stock Forecast page. More about Laekna, Inc. Laekna, Inc. is a Cayman Islands-incorporated company listed on the Hong Kong Stock Exchange. Operating in the biopharmaceutical sector, it focuses on developing and commercializing innovative therapies, with its corporate presence and shareholder base centered in mainland China and Hong Kong capital markets. Average Trading Volume: 2,661,812 Technical Sentiment Signal: Hold Current Market Cap: HK$5.82B For an in-depth examination of 2105 stock, go to TipRanks’ Overview page.</div>

02105

159859

159570

Laekna, Inc. has scheduled its annual general meeting for June 5, 2026, in Shanghai to seek shareholder approval for its 2025 audited financial statements, the re-election of directors, and to authorize share issuance up to 20% of its issued share capital. The company aims to enhance its capital flexibility for future growth. The latest analyst rating for Laekna's stock (HK:2105) is a Buy, with a price target of HK$24.16.

Tip Ranks

LAEKNA-B

Tianhong CNI BIOMEDICINE ETF

China Universal CNI HK Connect Innovative Drugs Industry ETF

China Southern Hang Seng Biotech ETF(QDII)

Minsheng Royal CSI Biotechnology Theme ETF

ChinaAMC CSI Biotechnology Theme ETF

GF CSI HK Innovative Drugs Industry ETF(QDII)

E Fund CSI Biotechnology Theme ETF

China Merchants CSI Biotechnology Theme ETF

First Trust NYSE Arca Biotech Index Fd

Hwabao WP CSI Pharmaceuticals ETF

Penghua SSE STAR Biology and Medicine ETF

Huaan Hang Seng Biotech ETF

Guotai CSI Bio-medicine ETF

Huatai-PB Hang Seng Innovative Drugs Industry ETF(QDII)

Laekna Sets 2026 AGM to Approve 2025 Results and Share Issuance Mandate